Journal
BREAST CARE
Volume 17, Issue 3, Pages 336-345Publisher
KARGER
DOI: 10.1159/000517501
Keywords
St. Gallen Consensus 2021; Early breast cancer; (Neo)adjuvant systemic treatment; Targeted therapy
Categories
Funding
- AstraZeneca GmbH
- Daiichi-Sankyo Deutschland GmbH
- Exact Sciences Deutschland GmbH
- Lilly Deutschland GmbH
- Mylan Germany GmbH
- Pierre Fabre Pharma GmbH
- Veracyte, Inc
Ask authors/readers for more resources
This article introduces the general topic and voting results of the 17th St. Gallen International Consensus Conference, emphasizing the importance of considering the individual cancer situation in treatment decisions. It also highlights the significance of the German evidence-based treatment guidelines in interpreting the voting results, with a focus on systemic treatment.
The general topic of this year's 17th St. Gallen (SG) International Consensus Conference on the treatment of patients with early breast cancer (SG-BCC) was Customizing local and systemic therapies for women with early breast cancer. This topic considers that each treatment decision must also consider the cancer-specific situation of the individual patient. This year, the votes of the SG-BCC were again discussed taking into account the multidisciplinary German S3 Guidelines and the recommendations of the Breast Cancer Working Group of the AGO (Arbeitsgemeinschaft Gynakologische Onkologie; AGO Mamma). As the international panel of the SG-BCC consists of experts from different countries, the votes do represent an international cross-section of opinions. Therefore, it is useful to discuss the voting results with respect to the German evidence-based treatment guidelines. This publication focuses mainly on systemic treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available